- Home
- RSSS vs BCAB Comparison
RSSS vs BCAB Comparison
Compare RSSS & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RSSS | BCAB |
|---|---|---|
| Founded | 2006 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.3M | 71.6M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | RSSS | BCAB |
|---|---|---|
| Price | $2.91 | $0.80 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | ★ $5.00 | $1.00 |
| AVG Volume (30 Days) | 74.7K | ★ 1.1M |
| Earning Date | 02-12-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $49,325,684.00 | N/A |
| Revenue This Year | $4.92 | N/A |
| Revenue Next Year | $7.09 | N/A |
| P/E Ratio | $70.77 | ★ N/A |
| Revenue Growth | ★ 5.83 | N/A |
| 52 Week Low | $2.32 | $0.24 |
| 52 Week High | $4.24 | $1.43 |
Technical Indicators
Market Signals| Indicator | RSSS | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 47.53 | 51.54 |
| Support Level | $2.82 | $0.63 |
| Resistance Level | $3.05 | $0.83 |
| Average True Range (ATR) | 0.14 | 0.09 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 41.54 | 73.41 |
Price Performance
Historical ComparisonAbout RSSS Research Solutions Inc
Research Solutions Inc is a holding company. The company provides vertical software-as-a-service ("SaaS") and artificial intelligence ("AI") solutions, providing software and related services to help research-intensive organizations simplify the research process, save time, and money. The company operates in a single segment, which derives its revenue from subscription fees from its cloud-based SaaS Platforms and transactional service fees for the electronic delivery of single articles. The company generates the majority of its revenue from the Transactions. Geographically, the company generates the majority of its revenue from the United States, followed by Europe.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.